NRx Pharmaceuticals, Inc.
NRXP
$3.28
$0.072.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.23M | 242.00K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.23M | 242.00K | -- | -- | -- |
| Cost of Revenue | 505.00K | 97.00K | -- | -- | -- |
| Gross Profit | 720.00K | 145.00K | -- | -- | -- |
| SG&A Expenses | 13.06M | 11.09M | 10.69M | 12.20M | 13.50M |
| Depreciation & Amortization | 68.00K | 27.00K | 3.00K | 3.00K | 3.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.41M | 15.47M | 14.13M | 17.45M | 19.70M |
| Operating Income | -16.19M | -15.23M | -14.13M | -17.45M | -19.70M |
| Income Before Tax | -28.62M | -38.06M | -33.79M | -24.11M | -25.13M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.62 | -38.06 | -33.79 | -24.11 | -25.13 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.62M | -38.06M | -33.79M | -24.11M | -25.13M |
| EBIT | -16.19M | -15.23M | -14.13M | -17.45M | -19.70M |
| EBITDA | -16.14M | -15.22M | -14.13M | -17.45M | -19.70M |
| EPS Basic | -1.57 | -2.32 | -2.21 | -1.98 | -2.38 |
| Normalized Basic EPS | -0.79 | -1.05 | -1.10 | -1.14 | -1.41 |
| EPS Diluted | -1.57 | -2.32 | -2.21 | -1.98 | -2.38 |
| Normalized Diluted EPS | -0.79 | -1.05 | -1.10 | -1.14 | -1.41 |
| Average Basic Shares Outstanding | 85.54M | 68.83M | 57.57M | 50.15M | 42.59M |
| Average Diluted Shares Outstanding | 85.54M | 68.83M | 57.57M | 50.15M | 42.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |